Sign In
Buy EDIT
$2.78
-0.0400 (-1.42%)
At Close: Jun 03, 2026
NASDAQ Jumps Over 1% as Tech Sparks Late Rally
12:00am, Tuesday, 05'th May 2020
Stocks Analysis by Zacks Investment Research covering: Microsoft Corporation, SPDR S&P 500, Apple Inc, Amazon.com Inc. Read Zacks Investment Research's latest article on Investing.com
Companies Like Editas Medicine (NASDAQ:EDIT) Are In A Position To Invest In Growth
12:25pm, Monday, 04'th May 2020
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
12:00am, Sunday, 03'rd May 2020
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
Editas Medicine Inc (NASDAQ:EDIT) Receives Consensus Rating of "Hold" from Analysts
05:52am, Saturday, 02'nd May 2020
Shares of Editas Medicine Inc (NASDAQ:EDIT) have been given a consensus recommendation of “Hold” by the nine analysts that are currently covering the stock, Marketbeat reports. One investment anal
How this Week’s Premium Top 10 Performed, May 1, 2020
08:06pm, Friday, 01'st May 2020
How this Week’s Premium Top 10 Performed, May 1, 2020
Posted by
Greg Harmon
on May 1st, 2020
Each week I post the performance of the stocks that were given to subscribers the previous Sunday. All pe
‘You don’t have to see to wrestle’: Legally blind Alabama HS senior chases state title
03:53pm, Thursday, 30'th Apr 2020
Jay Spencer of St. John Paul II in Huntsville has more than just a state tournament coming up - doctors believe they've developed a surgery that will cure his retinal disease.
Editas Medicine to Host Conference Call Discussing First Quarter 2020 Results and Corporate Update
12:05pm, Thursday, 30'th Apr 2020
CAMBRIDGE, Mass., April 30, 2020 -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on.
Editas Medicine initiates IND-enabling activities for EDIT-201 EDIT
01:33pm, Wednesday, 29'th Apr 2020
Editas Medicine initiates IND-enabling activities for EDIT-201 EDIT
BRIEF-Editas Medicine Initiates Ind-Enabling Activities For Edit-201
01:26pm, Wednesday, 29'th Apr 2020
Editas Medicine Inc:
Editas Medicine Initiates IND-enabling Activities for EDIT-201, an Allogeneic NK Cell Medicine for the Treatment of Solid Tumor Cancers
01:00pm, Wednesday, 29'th Apr 2020
Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced the initiation of IND-enabling activities for EDIT-201, an allogeneic natural killer (NK) cell medicine for the treatmen
How These 15 Stock Suggestions Fared Against the Market
04:44pm, Tuesday, 28'th Apr 2020
Motley Fool co-founder David Gardner revisits three Five-Stock Samplers and offers up lessons he learned to help you invest better.
Analysts Estimate Editas Medicine (EDIT) to Report a Decline in Earnings: What to Look Out for
04:33pm, Tuesday, 28'th Apr 2020
Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Editas Medicine (EDIT) to Report a Decline in Earnings: What to Look Out for
04:33pm, Tuesday, 28'th Apr 2020
Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Another Good Week for Biopharma and Diagnostics Stocks: Innovation is Driving Gains
08:05am, Monday, 27'th Apr 2020
As the market moves with COVID epidemiological data many stocks took a hit on questionable or incomplete news from the WHO on a clinical study in China on Remdesivir; Gilead Sciences stock took a hit
